Related Experiment Video

Updated: Apr 17, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Mohammad Atefi1, Bjoern Titz2, Earl Avramis3

  • 1Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), Los Angeles, CA, USA. matefi@ucla.edu.

Molecular Cancer
|February 4, 2015
PubMed
Abstract

Insights

Combining pan-RAF and MEK inhibitors effectively blocks NRAS-mutant melanoma cell growth. This targeted therapy shows promise by inhibiting key MAPK pathway signaling, offering a new strategy for melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • NRAS mutations occur in approximately 20% of melanomas, yet direct NRAS inhibitors are unavailable.
  • The MAPK pathway is a critical downstream signaling pathway for NRAS.
  • This study explores targeting the MAPK pathway to inhibit NRAS-driven oncogenic signaling.

Purpose of the Study:

  • To investigate the efficacy of inhibiting two key signaling points in the MAPK pathway.
  • To evaluate the effects of a pan-RAF inhibitor (PRi) and a MEK inhibitor (MEKi) on NRAS-mutant melanoma cells.

Main Methods:

  • Fourteen NRAS-mutant human melanoma cell lines were treated with a pan-RAF inhibitor (PRi) and a MEK inhibitor (MEKi), individually and in combination.
  • Assessed effects on cell proliferation, cell cycle progression, apoptosis, and gene expression profiles.

Main Results:

  • The combination of PRi and MEKi demonstrated significant synergistic growth inhibition in most cell lines.
  • Sensitive cell lines exhibited apoptosis induction and proliferation blockade, correlated with p-MEK levels and reduced cyclin D1 expression.
  • Resistant cell lines required combined MAPK pathway inhibition and cyclin D3 targeting for proliferation blockade, showing higher p-GSK3β levels.

Conclusions:

  • Combination therapy with PRi and MEKi is a potential effective regimen for NRAS-mutant melanomas.
  • Treatment efficacy is linked to high MAPK pathway activity and cellular dependence on this pathway for proliferation and survival.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K